GH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $40.00 price target on the stock.

Several other equities research analysts have also recently issued reports on the stock. Canaccord Genuity Group raised their price target on shares of GH Research from $30.00 to $31.00 and gave the stock a buy rating in a research note on Monday. JMP Securities cut their price objective on shares of GH Research from $50.00 to $39.00 and set a market outperform rating on the stock in a report on Friday, March 1st.

GH Research Price Performance

GH Research stock opened at $12.08 on Tuesday. GH Research has a 12-month low of $5.05 and a 12-month high of $14.64. The stock has a market capitalization of $628.52 million, a P/E ratio of -18.87 and a beta of 0.80. The firm’s 50-day moving average is $10.45 and its two-hundred day moving average is $8.04.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). As a group, analysts forecast that GH Research will post -0.96 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. PEAK6 Investments LLC lifted its holdings in shares of GH Research by 72.9% during the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after acquiring an additional 16,991 shares during the period. AdvisorShares Investments LLC lifted its holdings in shares of GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after acquiring an additional 1,977 shares during the period. Barclays PLC raised its holdings in GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after buying an additional 31,500 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in GH Research by 16.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company’s stock valued at $932,000 after buying an additional 12,911 shares during the period. Finally, Lynx1 Capital Management LP raised its holdings in GH Research by 13.8% in the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after buying an additional 133,804 shares during the period. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).